Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
Apatinib and SHR-1210 are new drugs produced by jiangsu hengrui pharmaceutical co., LTD. Both
are listed in China. The investigators want to design a trial to explore the efficacy and
safety of Apatinib and SHR-1210 in patients with solid tumors with only liver metastasis (as
second-line treatment). The main purpose is to evaluate the disease progression-free survival
(PFS) of Apatinib and SHR-1210 in patients with solid tumors with only liver metastasis
(progress after first-line treatment). The secondary purpose is to compare the total survival
period (OS); 1-year survival rate, 2-year survival rate; evaluation of drug safety;
exploration of related biomarkers in specific subgroups to predict effectiveness or adverse
reactions.